Molecular Profiling of Digestive Grade 3 Neuroendocrine Tumors Reveals a Shared Molecular Framework with Lower-Grade Tumors, Marked Heterogeneity, and Therapeutic Opportunities Amedeo Sciarra, Laura Libera, Annarita Destro, Roberta Maragliano, Daniela Furlan, Vincenzo Guastafierro, Deborah Marchiori, Alessandro Vanoli, Raul S. Gonzalez, Igor Letovanec, Stefano Lazzi, Stefano La Rosa, Silvia Uccella Endocrine Pathology, 2026 Well-differentiated neuroendocrine tumors, grade 3 (NETs G3) of the digestive system are high-grade neuroendocrine neoplasms characterized by well-differentiated neuroendocrine morphology and high proliferative activity. Their molecular identity and therapeutic vulnerabilities remain incompletely defined. We performed a transcriptomic analysis and a comprehensive genomic profiling of 40 cases, including 26 NETs G3, 8 NETs G1/G2, and 6 neuroendocrine carcinomas (NECs). Targeted sequencing assessed alterations at both the DNA and RNA level, and gene expression profiling was conducted using a targeted immune-oncology panel. NETs G3 retained recurrent alterations in chromatin-regulatory genes characteristic of well-differentiated tumors and largely lacked the consistent TP53 and RB1 inactivation typical of NECs. Transcriptomic and genomic analysis demonstrated separation of NECs from NETs, with NETs G3 partially overlapping with NETs G1/G2 supporting a model of molecular relatedness. However, when compared with NETs G1/G2, NETs G3 showed upregulation of extracellular matrix remodeling, metabolic reprogramming, and cytokine signaling pathways. NETs G3 were heterogeneous in terms of number of genomic alterations per case and involved genes. A distinctive genomic feature was the predominance of large-segment copy-number losses, frequently involving chromatin-regulatory regions on chromosomes X and 10. Potentially targetable alterations were detected in up to 25% of NETs G3. Analysis of immune microenvironment supported a poorly inflamed tumor status, with individual cases harboring microsatellite instability or enrichment in tumor-infiltrating lymphocytes potentially amenable to immunotherapy.
Loss of hormone receptor expression in breast tissue following pre-surgical therapy with an SERD Francesco de Napoli, Bethania Fernandes, Silvia Uccella, Margherita D'Arezzo, Martina Iuzzolino, Luca Di Tommaso Histopathology, 2026 Oestrogen receptors (ER) play a central role to breast carcinogenesis, making anti-oestrogen therapies a cornerstone in treatment for luminal-type tumours.1 Over the last years, Selective Oestrogen Receptor Degraders (SERDs) are being developed, but their effects on both neoplastic and non-neoplastic breast tissue remain poorly defined. Here, we present three cases in which SERD treatment was associated with unexpected histological changes in normal mammary tissue. Three female patients, aged between 39 and 48 years, underwent core needle biopsy for a clinical diagnosis of breast carcinoma. All tumours were diagnosed as No Special Type G2 and showed strong and diffuse positivity for ER (>90%) and progesterone receptors (PR, >90%), with high proliferation indices (Ki67, 10%–40%), while HER2 status was negative. One month after the biopsy, all patients underwent quadrantectomy. Surgical specimens were examined intraoperatively for macroscopic evaluation and subsequently processed according to standard fixation protocols. At histology, initial immunohistochemical assessment revealed an apparent loss of ER and PR expression, both within the tumour and in the adjacent non-neoplastic mammary tissue (Figure 1). Initially, fixation artefacts were considered; however, after discussion with the treating clinicians, we learned that all patients had received SERD therapy for about 4 weeks between biopsy and surgery. Once realized this important information, a closer inspection at higher magnification revealed faint nuclear ER staining in the benign parenchyma in all three cases (Figure 1). This internal control prompted a re-evaluation of the neoplastic tissue, revealing very low-intensity expression of ER (60%–90%) and PR (5%–90%), while Ki67 had markedly decreased (2%–10%). In two cases, HER2 status showed an increase in immunohistochemical scoring from baseline (from 0–1 to 2+) (Figure 2), although FISH testing showed no gene amplification. The three cases described in this report highlight a known but potentially risky phenomenon for pathologists. SERDs are well known to induce ER degradation in cancer cells, and it is reasonable to assume that they can also diminish ER and PR expression in benign glands. This phenomenon is rooted in their molecular mechanism of action. SERDs bind to the ER ligand-binding domain and induce a conformational change that disrupts the receptor's stability. The altered conformation promotes ubiquitin ligases recruitment, resulting in accelerated degradation of ER via the proteasome.1 If treatment history is not taken into account, an unaware observer might reclassify the cancer as a hormone receptor-negative phenotype, and this could dramatically alter postoperative management or raise questions about whether the initial biopsy was mistaken or whether a second primary tumour was present. Moreover, these three cases revealed a further unexpected finding: the shift in HER2 immunohistochemical score. Indeed, prolonged ER inibition sometimes leads to upregulation of alternative growth pathways in a subset of cells, as a mechanism of resistance. For instance, long-term fulvestrant treatment was associated with modest increases in HER2 expression in ~29% of tumours.2 Loss of ER input may relieve feedback inhibition on growth factor receptors or induce cells to rely more on HER2/EGFR signalling. These resistance mechanisms remind us that the pronounced initial suppression of ER/PR/Ki-67 by SERDs might not be permanent if the tumour eventually activates escape pathways.3 It is worth noting that some of the clinical trials conducted for SERD approval adopted the change in tumour Ki67 as a primary endpoint. A Ki67 value below 2.7% is considered indicative of complete cell cycle arrest according to ESMO guidelines and is regarded as a strong biomarker of endocrine therapy response, correlating with excellent prognosis.4 In conclusion, the presented cases illustrate that a short course of a novel SERD can almost abolish ER and PR from a luminal breast carcinoma and halt its proliferation, also affecting normal breast tissue. This finding, while exciting from a treatment perspective, could easily be misinterpreted without the proper context. Moreover, the indirect effect on HER2 expression warrants further investigation in order to clarify its biological significance and potential clinical implications. Open access funding provided by BIBLIOSAN. All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Dr. Francesco de Napoli and Prof. Luca Di Tommaso. The first draft of the manuscript was written by Francesco de Napoli and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. No funding was received to assist with the preparation of this manuscript. The authors have no competing interests to declare that are relevant to the content of this article. The data that support the findings of this study are available from the corresponding author upon reasonable request.
Implantation of cancer cells from transoral endoscopic thyroidectomy: a case report Daqi Zhang, Hui Sun, Matteo Annoni, Maria Laura Tanda, Silvia Uccella, Antonella Pino, Fausto Famà, Francesco Frattini, Dorotea Confalonieri, Simone Gianazza, Andrea Rizzi, Young Jun Chai, Hoon Yub Kim, Che Wei Wu, Angkoon Anuwong, Paolo Miccoli, Gianlorenzo Dionigi Gland Surgery, 2026 Background: With the development and new technological knowledge, such as surgical techniques that accompany the consolidated open surgical procedures, minimally invasive strategies have also emerged for thyroid surgery. Among these, we can cite the transoral endoscopic vestibular approach known as TOETVA. Recurrences and metastases of differentiated thyroid cancer frequently manifest in the lymph nodes, lungs, bones, and liver. Although the primary implantation of cancer cells causing these recurrences and metastases is considered an uncommon event, it can nonetheless occur in specific instances. This can be a serious complication for patients, as these recurrences and metastases can be difficult to detect and treat effectively. Early identification and appropriate management of these cases are crucial for improving patient outcomes. Case Description: We present a case of a 55-year-old male patient with recurring muscular and subcutaneous recurrence that developed five years after the initial left thyroidectomy performed via a TOETVA. The patient therefore required a second surgical procedure of completion thyroidectomy, central lymph node dissection (level 6 and 7), and removal of nodes in subcutaneous tissue and muscle. Conclusions: Tumor biology, local environment, technical issues, surgical skills, and the correct management and handling of neoplastic nodules represent crucial clinical pitfalls and important factors that can contribute to local recurrence and malignant cellular implantation following a TOETVA for thyroid surgery.
Neuroendocrine neoplasms of the stomach. Update on diagnostic criteria, classification, and prognostic markers Silvia Uccella, Stefano La Rosa Virchows Archiv, 2026 Gastric neuroendocrine neoplasms (gNENs) encompass all the spectrum of NENs including neuroendocrine carcinomas (gNECs), mixed neuroendocrine/non-neuroendocrine neoplasms (gMiNENs) and neuroendocrine tumors (gNETs). Differently from other digestive sites, gNETs are subclassified according to the clinicopathologic setting in which they arise, with important prognostic implications. Since gastric endoscopic biopsies represent a high-volume daily activity in both referral and community hospitals, pathologists should be increasingly aware of this disease. This will allow to correctly identify the different entities and, when present, their precursor lesions, giving useful information to clinicians for the best patient management. This review paper aims to provide morphologic, immunophenotypic, and, when necessary, molecular criteria for the correct diagnosis and subtyping of gNENs. In addition, a simplified prognostic classification schema of enterochromaffin-like (ECL)-cell NETs is proposed, based on gastrin serum levels and the status of gastric acid secretion.
Ciliogenesis in pancreatic neuroendocrine tumors: insight into the role of WDR60 Cristina Grassi, Alice Laffi, Alessandro Zerbi, Elisabetta Lavezzi, Gherardo Mazziotti, Silvia Uccella, Andrea Gerardo Lania, Eleonora Vitali Endocrine Related Cancer, 2025 Primary cilia have emerged as key regulators in cancer biology, influencing tumor progression and therapeutic response through diverse signaling pathways. In this study, we identify WDR60, a component of the dynein-2 complex essential for retrograde intraflagellar transport, as a novel modulator of pancreatic neuroendocrine tumor (Pa-NET) behavior. Transcriptomic analysis of the GEO dataset GSE73338 revealed that WDR60 is significantly upregulated in both primary and metastatic Pa-NETs compared to normal pancreatic islets. Moreover, WDR60 expression is higher in G2 compared to G1 Pa-NETs. Functional analyses in QGP-1 cells following WDR60 silencing demonstrated broad transcriptional reprogramming with enrichment of pathways related to cell adhesion and extracellular matrix (ECM) remodeling. Notably, WDR60 knockdown reduced cell migration and enhanced adhesion without affecting cell viability or proliferation. Among the key upregulated genes were PIK3AP1, RAP1B, and RFLNA, suggesting that WDR60 is involved in regulating PI3K/AKT signaling and cytoskeletal dynamics. To explore potential therapeutic implications, we examined the effects of Ciliobrevin A (HPI-04), an inhibitor of Hedgehog signaling and ciliogenesis. HPI-04 significantly reduced WDR60 expression, impaired cell migration, and increased adhesion. RT-qPCR confirmed overlapping gene expression changes between HPI-04 treatment and WDR60 silencing, although some differences, such as CD164 regulation, suggest WDR60-independent mechanisms. Collectively, these findings identify WDR60 as a critical regulator of cell motility and adhesion in Pa-NETs via ciliary signaling and cytoskeletal remodeling. They also support the therapeutic potential of targeting cilia-associated pathways, including WDR60 and Hedgehog signaling, in the treatment of Pa-NETs.
Neuroendocrine tumors in patients with inflammatory bowel disease: a case series Roberta Elisa Rossi, Benedetta Masoni, Giulia Migliorisi, Cristina Bezzio, Alexia Francesca Bertuzzi, Silvia Uccella, Andrea Gerardo Antonio Lania, Alessandro Zerbi, Antonino Spinelli, Cesare Hassan, Alessandro Repici, Alessandro Armuzzi Endocrine, 2025
Composite gangliocytoma/neuroma and neuroendocrine tumour: a contemporary analysis of 71 cases shows risk factors for metastasis Luiz M Nova‐Camacho, Changqing Ma, Ibrahim Abukhiran, Nuha Shaker, M‐Nasan Abdul Baki, Katrina Collins, Iván González, Timothy Chao, Zhaohai Yang, Monika Vyas, Michael Feely, Andrew M Bellizzi, Diana Agostini‐Vulaj, Aaron R Huber, Alexandros D Polydorides, Xinyang Xu, Stefano La Rosa, Jose J Paricio, Silvia Uccella, Maria L Alvarez, Ainhoa Ordoñez Arrillaga, Irune Ruiz Diaz, Dipti M Karamchandani, Claudio Luchini, Elena Verdú Martin, Tamara Zudaire Fuertes, Susana Rubio Mediavilla, Wei Xiong, Brian Cox, Raul S Gonzalez Histopathology, 2025
Misdiagnosing Bayesian statistics Vincenzo Guastafierro, Devin Nicole Corbitt, Alessandra Bressan, Bethania Fernandes, Ömer Mintemur, Francesca Magnoli, Susanna Ronchi, Stefano La Rosa, Silvia Uccella, Salvatore Lorenzo Renne Virchows Archiv, 2025
Clinical presentation of bone metastases in neuroendocrine tumors: a retrospective cohort study Elisabetta Lavezzi, Simona Jaafar, Isabella Chiardi, Alessandro Brunetti, Emanuela Morenghi, Roberta Elisa Rossi, Miriam Cellini, Maria Francesca Birtolo, Silvia Uccella, Alessandro Zerbi, Alice Laffi, Alexia Bertuzzi, Fabio Vescini, Gherardo Mazziotti, Andrea Gerardo Antonio Lania Endocrine Related Cancer, 2025
Unveiling the risks of ChatGPT in diagnostic surgical pathology Vincenzo Guastafierro, Devin N. Corbitt, Alessandra Bressan, Bethania Fernandes, Ömer Mintemur, Francesca Magnoli, Susanna Ronchi, Stefano La Rosa, Silvia Uccella, Salvatore Lorenzo Renne Virchows Archiv, 2025
Management of type I gastric-neuroendocrine tumors: the less the better? Roberta Elisa Rossi, Benedetta Masoni, Valeria Poletti, Roberta Maselli, Silvia Carrara, Alexia Francesca Bertuzzi, Silvia Uccella, Andrea Gerardo Antonio Lania, Alessandro Zerbi, Cesare Hassan, Alessandro Repici Frontiers in Endocrinology, 2025
Trends in Thyroid Fine-Needle Aspiration Cytology - Results from the Italian Cytopathology Committee National Practice Survey Gennaro Acanfora, , Mariantonia Nacchio, Carla Baronchelli, Amedeo Boscaino, Carolina Buriani, Elisabetta Carico, Andrea Cavazzana, Anna Maria Cesinaro, Doglioni Claudio, Immacolata Cozzolino, Anna Crescenzi, Stefania Damiani, Giovanni De Chiara, Gisele de Rezende, Ludovica de Vincentiis, Guido Fadda, Gerardo Ferrara, Pironi Flavio, Giacomo Gazzano, Annarita Gencarelli, Francesca Grillo, Leo Guidobaldi, Maria Letizia Lai, Gaetano Magro, Grazia Marangi, Fabio Pagni, Gianmaria Pennelli, Simonetta Piana, Michele Pirrelli, Stefano Pizzolitto, Giuseppina Renzulli, Esther Diana Rossi, Silvia Taccogna, Silvia Uccella, Clara Ugolini, Andrea Vecchione, Elena Vigliar, Marco Volante, Roberta Zappacosta, Francesco Alfredo Zito, Giovanni Tallini, Giancarlo Troncone, Claudio Bellevicine Pathologica, 2025
Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule Moufida Ben Nasr, Vera Usuelli, Sergio Dellepiane, Andy Joe Seelam, Teresa Vanessa Fiorentino, Francesca D’Addio, Emma Fiorina, Cong Xu, Yanan Xie, Hari Baskar Balasubramanian, Eduardo Castillo-Leon, Lara Loreggian, Anna Maestroni, Emma Assi, Cristian Loretelli, Ahmed Abdelsalam, Basset El Essawy, Silvia Uccella, Ida Pastore, Maria Elena Lunati, Gianmarco Sabiu, Adriana Petrazzuolo, Giacomo Ducci, Elena Sacco, Lucia Centofanti, Massimo Venturini, Serena Mazzucchelli, Deborah Mattinzoli, Masami Ikehata, Giuseppe Castellano, Gary Visner, Liu Kaifeng, Kang Mi Lee, Zhimin Wang, Domenico Corradi, Stefano La Rosa, Silvio Danese, Jun Yang, James F. Markmann, Gian Vincenzo Zuccotti, Reza Abdi, Franco Folli, Paolo Fiorina Cell Metabolism, 2024
Molecular characterization of diffuse large B-cell lymphomas associated with hepatitis C virus infection Roberta Sciarra, Michele Merli, Caterina Cristinelli, Marco Lucioni, Silvia Zibellini, Roberta Riboni, Daniela Furlan, Silvia Uccella, Caterina Zerbi, Benedetta Bianchi, Manuel Gotti, Virginia Valeria Ferretti, Chiara Varraso, Sara Fraticelli, Tanja Lazic, Irene Defrancesco, Barbara Mora, Laura Libera, Alessandro Mazzacane, Federico Carpi, Martha Berliner, Giuseppe Neri, Ettore Rizzo, Federica De Paoli, Fausto Sessa, Francesco Passamonti, Marco Paulli, Luca Arcaini British Journal of Haematology, 2024
Neuroendocrine Neoplasms of the Digestive System Irene Esposito, Günter Klöppel, Irene Esposito, Atsuko Kasajima, Stefano La Rosa, Levent Dizdar, Wolfram Trudo Knoefe, Matthias Schott, Clarisse Dromain, Nicolas Villard, Häberle Lena, Björn Konukiewitz, Aurel Perren, Ilaria Marinoni, Bence Sipos, Inga Boeck, Martin Anlauf, Moritz Jesinghaus, Silvia Uccella, Christoph Roderburg, Henning Jann, Emil Novruzov, Katalin Mattes‐György, Frederik L Giesel, Pietro Antonini, Antonio Pea, Alessandra Pulvirenti, Claudio Luchini Gastrointestinal Oncology A Critical Multidisciplinary Team Approach, 2024
Ampullary Neuroendocrine Neoplasms: Identification of Prognostic Factors in a Multicentric Series of 119 Cases Alessandro Vanoli, Oneda Grami, Catherine Klersy, Anna Caterina Milanetto, Luca Albarello, Matteo Fassan, Claudio Luchini, Federica Grillo, Paola Spaggiari, Frediano Inzani, Silvia Uccella, Paola Parente, Gennaro Nappo, Paola Mattiolo, Massimo Milione, Andrea Pietrabissa, Lorenzo Cobianchi, Marco Schiavo Lena, Stefano Partelli, Antonio Di Sabatino, Christine Sempoux, Carlo Capella, Claudio Pasquali, Claudio Doglioni, Fausto Sessa, Aldo Scarpa, Guido Rindi, Marco Paulli, Alessandro Zerbi, Massimo Falconi, Enrico Solcia, Stefano La Rosa Endocrine Pathology, 2022
SARS-CoV-2 detection in primary thyroid sarcoma: coincidence or interaction? M. L. Tanda, S. Ippolito, D. Gallo, A. Baj, F. Novazzi, A. Genoni, M. Annoni, N. Mancini, N. Clementi, G. Finzi, E. Piantanida, P. Premoli, A. Lai, D. Dalla Gasperina, F. Maggi, S. Uccella Journal of Endocrinological Investigation, 2022
Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms Guido Rindi, Ozgur Mete, Silvia Uccella, Olca Basturk, Stefano La Rosa, Lodewijk A. A. Brosens, Shereen Ezzat, Wouter W. de Herder, David S. Klimstra, Mauro Papotti, Sylvia L. Asa Endocrine Pathology, 2022
Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification Sylvia L. Asa, Ozgur Mete, Michael D. Cusimano, Ian E. McCutcheon, Arie Perry, Shozo Yamada, Hiroshi Nishioka, Olivera Casar-Borota, Silvia Uccella, Stefano La Rosa, Ashley B. Grossman, Shereen Ezzat, International Pituitary Pathology, Sofia Asioli, Süheyla Uyar Bozkurt, Nil Comunoglu, Giulia Cossu, Peter Earls, Nuperi Gazioglu, Richard A. Hickman, Hidetoshi Ikeda, Emilija Manojlovic-Gacic, Mahmoud Messerer, Buge Öz, Sara Pakbaz, Federico Roncaroli, Wolfgang Saeger, John Turchini, Sema Yarman Modern Pathology, 2021
Neuroendocrine neoplasms of the gut Stefano La Rosa, Silvia Uccella, Guido Rindi Spectrum of Neuroendocrine Neoplasia A Practical Approach to Diagnosis Classification and Therapy, 2020
Genitourinary neuroendocrine neoplasms Silvia Uccella, Xavier Mathias-Guiu, Stefano La Rosa Spectrum of Neuroendocrine Neoplasia A Practical Approach to Diagnosis Classification and Therapy, 2020
Neuroendocrine neoplasms of the breast Silvia Uccella, Giovanna Finzi, Stefano La Rosa, Fausto Sessa Spectrum of Neuroendocrine Neoplasia A Practical Approach to Diagnosis Classification and Therapy, 2020
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group Barbara Mora, Paola Guglielmelli, Elisa Rumi, Margherita Maffioli, Daniela Barraco, Alessandro Rambaldi, Marianna Caramella, Rami S. Komrokji, Jean‐Jacques Kiladjian, Jason Gotlib, Alessandra Iurlo, Francisco Cervantes, Timothy Devos, Francesca Palandri, Valerio De Stefano, Marco Ruggeri, Richard T. Silver, Francesco Albano, Giulia Benevolo, Chiara Cavalloni, Silvia Uccella, Raffaella Accetta, Claudia Siracusa, Stefania Agnoli, Michele Merli, Tiziano Barbui, Lorenza Bertù, Mario Cazzola, Alessandro M. Vannucchi, Francesco Passamonti American Journal of Hematology, 2020
Gene translocations in testicular lymphomas Barbara Bernasconi, Silvia Uccella, Vittoria Martin, Luca Mazzucchelli, Fausto Sessa, Carlo Capella, Maria Grazia Tibiletti Leukemia and Lymphoma, 2014
Clinical and molecular characterization of diffuse large b-cell lymphomas with 13q14.3 deletion M. Mian, M. Scandurra, E. Chigrinova, Y. Shen, G. Inghirami, T.C. Greiner, W.C. Chan, J.M. Vose, M. Testoni, A. Chiappella, L. Baldini, M. Ponzoni, A.J.M. Ferreri, S. Franceschetti, G. Gaidano, S. Montes-Moreno, M.A. Piris, F. Facchetti, A. Tucci, J.Fr. Nomdedeu, T. Lazure, S. Uccella, M.G. Tibiletti, E. Zucca, I. Kwee, F. Bertoni Annals of Oncology, 2012
Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome Ekaterina Chigrinova, Michael Mian, Marta Scandurra, Timothy C. Greiner, Wing C. Chan, Julie M. Vose, Giorgio Inghirami, Annalisa Chiappella, Luca Baldini, Maurilio Ponzoni, Andrés J.M. Ferreri, Silvia Franceschetti, Gianluca Gaidano, Alessandra Tucci, Fabio Facchetti, Thierry Lazure, Olivier Lambotte, Santiago Montes‐Moreno, Miguel A. Piris, Josep Fr. Nomdedeu, Silvia Uccella, Paola M.V. Rancoita, Ivo Kwee, Emanuele Zucca, Francesco Bertoni Hematological Oncology, 2011
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome Andrea Rinaldi, Michael Mian, Ekaterina Chigrinova, Luca Arcaini, Govind Bhagat, Urban Novak, Paola M. V. Rancoita, Cassio P. De Campos, Francesco Forconi, Randy D. Gascoyne, Fabio Facchetti, Maurilio Ponzoni, Silvia Govi, Andrés J. M. Ferreri, Manuela Mollejo, Miguel A. Piris, Luca Baldini, Jean Soulier, Catherine Thieblemont, Vincenzo Canzonieri, Valter Gattei, Roberto Marasca, Silvia Franceschetti, Gianluca Gaidano, Alessandra Tucci, Silvia Uccella, Maria Grazia Tibiletti, Stephan Dirnhofer, Claudio Tripodo, Claudio Doglioni, Riccardo Dalla Favera, Franco Cavalli, Emanuele Zucca, Ivo Kwee, Francesco Bertoni Blood, 2011
Genomic lesions associated with a different clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP-21 Marta Scandurra, Michael Mian, Timothy C. Greiner, Paola M. V. Rancoita, Cassio P. De Campos, Wing C. Chan, Julie M. Vose, Ekaterina Chigrinova, Giorgio Inghirami, Annalisa Chiappella, Luca Baldini, Maurilio Ponzoni, Andres J.M. Ferreri, Silvia Franceschetti, Gianluca Gaidano, Santiago Montes‐Moreno, Miguel A. Piris, Fabio Facchetti, Alessandra Tucci, Josep Fr. Nomdedeu, Thierry Lazure, Olivier Lambotte, Silvia Uccella, Graziella Pinotti, Giancarlo Pruneri, Giovanni Martinelli, Ken H. Young, Maria Grazia Tibiletti, Andrea Rinaldi, Emanuele Zucca, Ivo Kwee, Francesco Bertoni British Journal of Haematology, 2010
Syk expression patterns differ among B-cell lymphomas Maurilio Ponzoni, Silvia Uccella, Michael Mian, Andrea Rinaldi, Fabio Facchetti, Giancarlo Pruneri, Gianluca Gaidano, Carlo Capella, Emanuele Zucca, Claudio Doglioni, Francesco Bertoni Leukemia Research, 2010
Aneuploidy, centrosome alteration and securin overexpression as features of pituitary somatotroph and lactotroph adenomas Analytical and Quantitative Cytology and Histology, 2005
Espressione di Inibina A ed Activina A nelle cellule endocrine normali e nei tumori endocrini del pancreas Pathologica, 1998
High expression of growth factors and growth factor receptors in ovarian metastases from ileal carcinoids: An immunohistochemical study of 2 cases Archives of Pathology and Laboratory Medicine, 1998
Molecular Profiling of Digestive Grade 3 Neuroendocrine Tumors Reveals a Shared Molecular Framework with Lower-Grade Tumors, Marked Heterogeneity, and Therapeutic Opportunities A Sciarra, L Libera, A Destro, R Maragliano, D Furlan, V Guastafierro, ... Endocrine Pathology 37 (1), 23 , 2026 2026
Ampullary Mixed Adenoma and Well-Differentiated Neuroendocrine Tumor (MANET) with Aberrant Beta-Catenin Expression in a Patient with Neurofibromatosis Type 1 DP Bouklas, V Guastafierro, S Carrara, A Zerbi, S Uccella Endocrine Pathology 37 (1), 10 , 2026 2026
Pituitary blastoma in a dog: comparative clinical, imaging, and pathologic features of a newly recognized and rare human entity G Giglia, C Falzone, ML Graceffa, S Uccella, MT Mandara Acta Neuropathologica Communications , 2026 2026
Radiological–pathological correlation of Head and Neck Cancer International Group (HNCIG) criteria for extranodal extension across imaging modalities: A retrospective cohort study C Giannitto, G Mari, S Pindilli, F Gaino, M Dassie, AA Esposito, ... European Journal of Radiology, 112872 , 2026 2026
AI-powered analysis of pancreatic ductal adenocarcinoma tissues to study the tumor immune ecosystem and identify novel classifiers. R Polidori, M Viatore, AR Putignano, G Donisi, C Giovanni, A Bonometti, ... Cancer Research 86 (7_Supplement), 83-83 , 2026 2026
Spatial and molecular profiling of multinucleated giant macrophages in pancreatic ductal adenocarcinoma M Viatore, R Polidori, AR Putignano, A Bonometti, S Uccella, S Bozzarelli, ... Cancer Research 86 (7_Supplement), 1589-1589 , 2026 2026
CtDNA as a biomarker in Salivary Gland Cancer (SAGACE trial) F Riva, F Gaino, E Stucchi, C Gurizzan, R Zadro, S Marchini, L Paracchini, ... Radiotherapy and Oncology 216, S6-S7 , 2026 2026
Beyond binary ENE in HPV-related oropharyngeal cancer: Toward standardized reporting and risk stratification A Costantino, P Bossi, S Uccella, G Spriano, C Giannitto Oral Oncology, 107909 , 2026 2026 Citations: 1
Implantation of cancer cells from transoral endoscopic thyroidectomy: a case report D Zhang, H Sun, M Annoni, ML Tanda, S Uccella, A Pino, F Famà, ... Gland Surgery 15 (1), 26 , 2026 2026
The Clinician’s Role in Diagnostic Pathways and the Impact of Clinicopathological Collaboration on Outcomes in Patients with Neuroendocrine Neoplasms: Current Perspectives A Laffi, A Lania, A Zerbi, E Lavezzi, S Carrara, S Uccella Neuroendocrinology 116 (1), 55-61 , 2026 2026
Adult Pancreatoblastoma: A Challenge in the Differential Diagnosis of Pancreatic Neuroendocrine Neoplasms V Guastafierro, DP Bouklas, S Pancetti, S Uccella Endocrine Pathology 36 (1), 52 , 2025 2025 Citations: 1
Ciliogenesis in pancreatic neuroendocrine tumors: insight into the role of WDR60 C Grassi, A Laffi, A Zerbi, E Lavezzi, G Mazziotti, S Uccella, AG Lania, ... Endocrine-Related Cancer 32 (12) , 2025 2025
Composite gangliocytoma/neuroma and neuroendocrine tumour: a contemporary analysis of 71 cases shows risk factors for metastasis LM Nova‐Camacho, C Ma, I Abukhiran, N Shaker, MN Abdul Baki, ... Histopathology 87 (6), 933-942 , 2025 2025 Citations: 1
Clinicopathological correlates of hormone expression-based subtypes of non-functioning duodenal/ampullary neuroendocrine tumors: a multicenter study of 151 cases A Vanoli, N Piva, FS Inzani, F Grillo, C Klersy, S Uccella, P Spaggiari, ... Endocrine Pathology 36 (1), 18 , 2025 2025 Citations: 2
Is ectopic Cushing syndrome commonly associated with small cell lung cancer (SCLC)? critical review of the literature and ACTH expression in resected SCLC A Ura, E Moser, M Evert, K Evert, B Märkl, E Sipos, M Kremer, H Sasano, ... Endocrine Pathology 36 (1), 16 , 2025 2025 Citations: 3
Neuroendocrine neoplasms of the stomach. Update on diagnostic criteria, classification, and prognostic markers S Uccella, S La Rosa Virchows Archiv, 1-16 , 2025 2025 Citations: 6
Trends in Thyroid Fine-Needle Aspiration Cytology-Results from the Italian Cytopathology Committee National Practice Survey G Acanfora, M Nacchio, C Baronchelli, A Boscaino, C Buriani, E Carico, ... Pathologica 117 (4), 309 , 2025 2025 Citations: 1
Loss of hormone receptor expression in breast tissue following pre‐surgical therapy with an SERD F De Napoli, B Fernandes, S Uccella, M D'arezzo, M Iuzzolino, ... Histopathology 88 (5), 1099 , 2025 2025
Trends in Thyroid Fine-Needle Aspiration Cytology-Results from the Italian Cytopathology Committee National Practice Survey: Trends in Thyroid FNAC–2022 Italian Survey G Acanfora, M Nacchio, C Baronchelli, A Boscaino, C Buriani, E Carico, ... Pathologica-Journal of the Italian Society of Anatomic Pathology and … , 2025 2025
Neuroendocrine tumors in patients with inflammatory bowel disease: a case series RE Rossi, B Masoni, G Migliorisi, C Bezzio, AF Bertuzzi, S Uccella, ... Endocrine, 1-5 , 2025 2025
MOST CITED SCHOLAR PUBLICATIONS
Overview of the 2022 WHO classification of neuroendocrine neoplasms G Rindi, O Mete, S Uccella, O Basturk, S La Rosa, LAA Brosens, S Ezzat, ... Endocrine pathology 33 (1), 115-154 , 2022 2022 Citations: 1167
Genomic and expression profiling identifies the B‐cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma A Rinaldi, I Kwee, M Taborelli, C Largo, S Uccella, V Martin, G Poretti, ... British journal of haematology 132 (3), 303-316 , 2006 2006 Citations: 277
Mixed neuroendocrine-nonneuroendocrine neoplasms (MiNENs): unifying the concept of a heterogeneous group of neoplasms S La Rosa, F Sessa, S Uccella Endocrine pathology 27 (4), 284-311 , 2016 2016 Citations: 248
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome A Rinaldi, M Mian, E Chigrinova, L Arcaini, G Bhagat, U Novak, ... Blood, The Journal of the American Society of Hematology 117 (5), 1595-1604 , 2011 2011 Citations: 235
Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors S La Rosa, C Klersy, S Uccella, L Dainese, L Albarello, A Sonzogni, ... Human pathology 40 (1), 30-40 , 2009 2009 Citations: 227
Long-term beneficial effect of islet transplantation on diabetic macro-/microangiopathy in type 1 diabetic kidney-transplanted patients P Fiorina, F Folli, F Bertuzzi, P Maffi, G Finzi, M Venturini, C Socci, ... Diabetes care 26 (4), 1129-1136 , 2003 2003 Citations: 224
Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features S La Rosa, S Uccella, G Finzi, L Albarello, F Sessa, C Capella Human pathology 34 (1), 18-27 , 2003 2003 Citations: 165
BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and … MG Tibiletti, V Martin, B Bernasconi, B Del Curto, L Pecciarini, S Uccella, ... Human pathology 40 (5), 645-652 , 2009 2009 Citations: 141
Mixed endocrine-exocrine tumors of the gastrointestinal tract. C Capella, S La Rosa, S Uccella, P Billo, M Cornaggia Seminars in diagnostic pathology 17 (2), 91-103 , 2000 2000 Citations: 132
The Hayman technique: a simple method to treat postpartum haemorrhage F Ghezzi, A Cromi, S Uccella, L Raio, P Bolis, D Surbek BJOG: An International Journal of Obstetrics & Gynaecology 114 (3), 362-365 , 2007 2007 Citations: 131
A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal C Villa, A Vasiljevic, ML Jaffrain-Rea, O Ansorge, S Asioli, V Barresi, ... Virchows Archiv 475 (6), 687-692 , 2019 2019 Citations: 130
Microallelotyping defines the monoclonal or the polyclonal origin of mixed and collision endocrine-exocrine tumors of the gut D Furlan, R Cerutti, A Genasetti, G Pelosi, S Uccella, S La Rosa, ... Laboratory investigation 83 (7), 963-971 , 2003 2003 Citations: 124
Immunohistochemical biomarkers of gastrointestinal, pancreatic, pulmonary, and thymic neuroendocrine neoplasms S Uccella, S La Rosa, M Volante, M Papotti Endocrine pathology 29 (2), 150-168 , 2018 2018 Citations: 121
Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification SL Asa, O Mete, MD Cusimano, IE McCutcheon, A Perry, S Yamada, ... Modern Pathology 34 (9), 1634-1650 , 2021 2021 Citations: 106
Classification of neuroendocrine neoplasms: lights and shadows S La Rosa, S Uccella Reviews in endocrine and metabolic disorders 22 (3), 527-538 , 2021 2021 Citations: 105
ACTH-secreting pancreatic neoplasms associated with Cushing syndrome: clinicopathologic study of 11 cases and review of the literature R Maragliano, A Vanoli, L Albarello, M Milione, O Basturk, DS Klimstra, ... The American journal of surgical pathology 39 (3), 374-382 , 2015 2015 Citations: 105
Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule MB Nasr, V Usuelli, S Dellepiane, AJ Seelam, TV Fiorentino, F D’Addio, ... Cell metabolism 36 (6), 1302-1319. e12 , 2024 2024 Citations: 93
CDX2 as a marker of intestinal EC-cells and related well-differentiated endocrine tumors S La Rosa, E Rigoli, S Uccella, AM Chiaravalli, C Capella Virchows Archiv 445 (3), 248-254 , 2004 2004 Citations: 93
Genomics of high-grade neuroendocrine neoplasms: well-differentiated neuroendocrine tumor with high-grade features (G3 NET) and neuroendocrine carcinomas (NEC) of various … S Uccella, S La Rosa, J Metovic, D Marchiori, JY Scoazec, M Volante, ... Endocrine pathology 32 (1), 192-210 , 2021 2021 Citations: 92
Prognostic and biological significance of cytokeratin 19 in pancreatic endocrine tumours S La Rosa, E Rigoli, S Uccella, R Novario, C Capella Histopathology 50 (5), 597-606 , 2007 2007 Citations: 87
